Clinical Trial

SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a single-arm, open-label, prospective, and exploratory investigation aimed at examining the short-term efficacy, specifically the objective response rate (ORR), of SBRT combined with Nimotuzumab followed by Tislelizumab in patients with recurrent/metastatic nasopharyngeal carcinoma who have experienced oligoprogression (1-5 metastatic lesions) after immunotherapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-11-05.
Status change: Enrolling by Invitation → Recruiting 2025-06-30
Trial Details
NCT Number NCT06676722
Lead Sponsor The First Affiliated Hospital of Xiamen University
Conditions Nasopharyngeal Cancinoma (NPC), SBRT, Immunotherapy
Enrollment 20 participants
Start Date 2024-11-05
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-07-01